Fobi AI Provides Clarification On Total Holdings Previously Provided In The Companys Information Circular
December 06, 2024 20:43 ET | Source: Fobi AI Inc. VANCOUVER, British…
Fobi AI Provides Update on Current Cease Trade Order
December 06, 2024 20:34 ET | Source: Fobi AI Inc. VANCOUVER, British…
Voxtur Announces Amendments to Financial Statements and MD&A forQ3 Ended September 30, 2024
December 06, 2024 18:16 ET | Source: Voxtur Analytics Corp. TORONTO and…
Cerence AI Announces Equity Grant to Employee Under Inducement Plan Pursuant to Nasdaq Listing Rule 5635(c)(4)
BURLINGTON, Mass., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Cerence Inc. (NASDAQ: CRNC)…
VivoPower to host Annual General Meeting on December 30, 2024 in London
London, Dec. 06, 2024 (GLOBE NEWSWIRE) -- VivoPower International PLC (NASDAQ: VVPR)…
Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) Patients
December 08, 2024 12:00 ET | Source: Affimed N.V. The combination of…
Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
December 08, 2024 12:00 ET | Source: Cogent Biosciences, Inc. 52% ORR…
DARZALEX (daratumumab) subcutaneous formulation shows 51 percent reduction in risk of progression to active multiple myeloma for patients with high-risk smouldering multiple myeloma
First subcutaneous anti-CD38 therapy to demonstrate potential to prevent end-organ damage, and…
Investigational Epcoritamab (DuoBody CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis
Media ReleaseCOPENHAGEN, Denmark; December 8, 2024 Preliminary analyses from the EPCORE® CLL-1…
Investigational Epcoritamab (DuoBody CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
Media ReleaseCOPENHAGEN, Denmark; December 7, 2024 Results show 96 percent overall response…